Key result
Cardiac myosin inhibitors target hypercontractility to improve oHCM symptoms alongside novel non-surgical septal therapies.
Why the study?
Traditional therapies for obstructive hypertrophic cardiomyopathy lack disease-modifying effects, while cardiac myosin inhibitors face logistical limitations and require ongoing investigation into long-term outcomes.
Answers are grounded in this paper and cite their sources.
Cardiac myosin inhibitors represent a major advance in oHCM treatment by directly targeting disease pathophysiology, while emerging pharmacological and invasive therapies aim to further refine management and overcome current limitations.
Hypertrophic cardiomyopathy is a prevalent condition characterised by ventricular hypertrophy, which results in left ventricular outflow obstruction in two-thirds of patients. Traditional pharmacological therapies, including β-blockers, calcium channel blockers and disopyramide, have been the cornerstone of symptom management but lack disease-modifying effects. The introduction of cardiac myosin inhibitors as the first therapy to directly target sarcomeric hypercontractility has dramatically changed clinical practice. However, several logistical factors presently limit the widespread adoption of cardiac myosin inhibitors, and their long-term side-effects and outcomes require ongoing investigation. Emerging pharmacological approaches, including EDG-7500 and gene therapies, aim to refine treatment strategies. For patients with refractory symptoms, invasive septal reduction therapies, including surgical myectomy and alcohol septal ablation, remain critical. Innovations such as radiofrequency ablation and septal scoring along the midline endocardium (SESAME) offer promising, minimally invasive alternatives. As treatment options expand, optimising patient selection, monitoring protocols and long-term outcomes remain essential to advancing care for patients with obstructive hypertrophic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2025) conducted a review in Hypertrophic cardiomyopathy with obstructive physiology (oHCM). Pharmacological and invasive therapies (cardiac myosin inhibitors, septal reduction therapies) was evaluated. Cardiac myosin inhibitors directly target sarcomeric hypercontractility to improve symptoms in obstructive hypertrophic cardiomyopathy, while novel minimally invasive septal reduction therapies offer alternatives to surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: